Premium
Conformational Modulation of Iduronic Acid‐Containing Sulfated Glycosaminoglycans by a Polynuclear Platinum Compound and Implications for Development of Antimetastatic Platinum Drugs
Author(s) -
Gorle Anil K.,
Haselhorst Thomas,
Katner Samantha J.,
EverestDass Arun V.,
Hampton James D.,
Peterson Erica J.,
Koblinski Jennifer E.,
Katsuta Eriko,
Takabe Kazuaki,
Itzstein Mark,
BernersPrice Susan J.,
Farrell Nicholas P.
Publication year - 2021
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.202013749
Subject(s) - chemistry , iduronic acid , platinum , glycosidic bond , sulfation , monosaccharide , stereochemistry , adduct , residue (chemistry) , crystallography , glycosaminoglycan , biochemistry , heparan sulfate , organic chemistry , catalysis , enzyme
1 H NMR spectroscopic studies on the 1:1 adduct of the pentasaccharide Fondaparinux (FPX) and the substitution‐inert polynuclear platinum complex TriplatinNC show significant modulation of geometry around the glycosidic linkages of the FPX constituent monosaccharides. FPX is a valid model for the highly sulfated cell signalling molecule heparan sulfate (HS). The conformational ratio of the 1 C 4 : 2 S 0 forms of the FPX residue IdoA(2S) is altered from ca. 35:65 (free FPX) to ca. 75:25 in the adduct; the first demonstration of a small molecule affecting conformational changes on a HS oligosaccharide. Functional consequences of such binding are suggested to be inhibition of HS cleavage in MDA‐MB‐231 triple‐negative breast cancer (TNBC) cells. We further describe inhibition of metastasis by TriplatinNC in the TNBC 4T1 syngeneic tumour model. Our work provides insight into a novel approach for design of platinum drugs (and coordination compounds in general) with intrinsic anti‐metastatic potential.